The therapy for the future

Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...
C&EN

Codelivery of Que and BCL-2 siRNA with Lipid–Copolymer Hybrid Nanocomplexes for Efficient Tumor Regression

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...
Le Lézard

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is ...
The Malaysian Reserve

The Next Chapter in Obesity Therapeutics: Vial’s INHBE siRNA Draws KOL Praise as a Next-Generation Obesity Therapy

EXECUTIVE SUMMARYVial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE ...

Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

Alnylam Announces Health Canada Approval of AMVUTTRA(R) (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...
The Malaysian Reserve

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today ...
Forbes

Gene Editing Or Gene Silencing: The Therapies Poised To Transform Medicine

Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...